Amarin reported $58.63M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Aerie Pharmaceuticals AERI:US $ 29.57M 6.52M
Alnylam Pharmaceuticals ALNY:US $ 184.01M 6.38M
Amarin AMRN:US $ 58.63M 13.76M
AstraZeneca AZN:LN 8.87B 244M
Biocryst Pharmaceuticals BCRX:US $ 65.28M 15.6M
Epizyme EPZM:US $ 6.06M 2.37M
Esperion Therapeutics ESPR:US $ 9.66M 2.05M
GlaxoSmithKline GSK:LN 4.79B 1.34B
Halozyme Therapeutics HALO:US $ 101.36M 20.94M
Heron Therapeutics HRTX:US $ 12.1M 2.39M
Intercept Pharmaceuticals ICPT:US $ 71.45M 16.38M
IONIS PHARMACEUT IONS:US $ 137.75M 300.03M
JAZZ PHA JAZZ:US $ 808.67M 110.23M
Nektar Therapeutics NKTR:US $ 16.47M 3.04M
Neurocrine Biosciences NBIX:US $ 373.4M 67.4M
Novartis NOVN:VX 9.34B 277M
Teva Pharmaceutical Industries TEVA:US $ 1828M 26M